IL6R and neoplasm: Several preclinical studies have shown significantly improved tumor control and survival with combination IL-6 blockade (anti-IL6 or anti-IL-6R) and ICI compared with ICI alone, which was postulated to be due to improved Th1/Th17 skewing (49–53).